The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure

Severe aplastic anemia (SAA) is a rare disease characterized by severe pancytopenia and bone marrow failure. Most patients with AA respond to immunosuppressive therapy (IST), usually as antithymocyte globulin (ATG) and cyclosporine (CsA), but some relapse on CsA withdrawal or require long-term admin...

Full description

Saved in:
Bibliographic Details
Main Authors: Shaoxue Ding, Xiaowei Liang, Tian Zhang, Rong Fu
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2020/1798795
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832560054784491520
author Shaoxue Ding
Xiaowei Liang
Tian Zhang
Rong Fu
author_facet Shaoxue Ding
Xiaowei Liang
Tian Zhang
Rong Fu
author_sort Shaoxue Ding
collection DOAJ
description Severe aplastic anemia (SAA) is a rare disease characterized by severe pancytopenia and bone marrow failure. Most patients with AA respond to immunosuppressive therapy (IST), usually as antithymocyte globulin (ATG) and cyclosporine (CsA), but some relapse on CsA withdrawal or require long-term administration of CsA to maintain blood counts. Recent research has found that rapamycin (Rapa) was an effective therapy in mouse models of immune-mediated bone marrow failure. However, it has not achieved a satisfactory effect in clinical application. At present, many studies have confirmed that eltrombopag (ELT) combined with IST can improve the curative effect of AA patients. Then, whether Rapa combined Elt in the treatment of AA will acquire better efficacy than a single drug application remains unclear. In this study, an immune attack-mediated AA mouse model was constructed by total body irradiation (TBI) and allo-lymphocyte infusion. In our study, we tested the efficacy of Rapa combined with Elt as a new treatment in mouse models of immune-mediated bone marrow failure. It showed that treatment with Rapa in combination Elt in the AA mouse model ameliorated pancytopenia and extended animal survival in a manner comparable to the standard dose of CsA and Rapa alone. However, there was no significant improvement effect on the number and function of NK cells and their subsets, mDCs, and CD4+/CD8+ ratio in AA mice after the therapy of Rapa combined with Elt compared with Rapa alone. Furthermore, the secretion of IL-10 of Tregs in AA mice increased significantly after the therapy of Rapa combined with Elt, but there was no significant difference in the number of Treg cells. We did not observe the difference in the curative effect of the Rapa group and CsA group, but for IL-10/Tregs ratio, the Rapa group was superior to the CsA group. And the IFN-r secretion of CD8+T cells in AA mice decreased significantly after the combination therapy of Rapa and Elt than Rapa alone. Compared with the AA group, the level of plasma IFN-γ, IL-2, and TNF-α decreased significantly (P<0.05), but IL-10, IL-4, IL-5, and IL-1β increased significantly in the Rapa group (P<0.05). As for IL-10, IL-12p70, IL-2, IL-6, KC/GRO, and TNF-α, the therapy of Rapa combined with Elt showed a more significant effect than Rapa alone in AA mice. To some extent, this study had shown a relatively better synergistic effect in murine models of immune-mediated bone marrow failure after the combination therapy of Rapa and Elt, which was a promising clinical utility in SAA treatment.
format Article
id doaj-art-a85e074725104f199515b5b591a01fbb
institution Kabale University
issn 2314-8861
2314-7156
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-a85e074725104f199515b5b591a01fbb2025-02-03T01:28:30ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/17987951798795The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow FailureShaoxue Ding0Xiaowei Liang1Tian Zhang2Rong Fu3Department of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaSevere aplastic anemia (SAA) is a rare disease characterized by severe pancytopenia and bone marrow failure. Most patients with AA respond to immunosuppressive therapy (IST), usually as antithymocyte globulin (ATG) and cyclosporine (CsA), but some relapse on CsA withdrawal or require long-term administration of CsA to maintain blood counts. Recent research has found that rapamycin (Rapa) was an effective therapy in mouse models of immune-mediated bone marrow failure. However, it has not achieved a satisfactory effect in clinical application. At present, many studies have confirmed that eltrombopag (ELT) combined with IST can improve the curative effect of AA patients. Then, whether Rapa combined Elt in the treatment of AA will acquire better efficacy than a single drug application remains unclear. In this study, an immune attack-mediated AA mouse model was constructed by total body irradiation (TBI) and allo-lymphocyte infusion. In our study, we tested the efficacy of Rapa combined with Elt as a new treatment in mouse models of immune-mediated bone marrow failure. It showed that treatment with Rapa in combination Elt in the AA mouse model ameliorated pancytopenia and extended animal survival in a manner comparable to the standard dose of CsA and Rapa alone. However, there was no significant improvement effect on the number and function of NK cells and their subsets, mDCs, and CD4+/CD8+ ratio in AA mice after the therapy of Rapa combined with Elt compared with Rapa alone. Furthermore, the secretion of IL-10 of Tregs in AA mice increased significantly after the therapy of Rapa combined with Elt, but there was no significant difference in the number of Treg cells. We did not observe the difference in the curative effect of the Rapa group and CsA group, but for IL-10/Tregs ratio, the Rapa group was superior to the CsA group. And the IFN-r secretion of CD8+T cells in AA mice decreased significantly after the combination therapy of Rapa and Elt than Rapa alone. Compared with the AA group, the level of plasma IFN-γ, IL-2, and TNF-α decreased significantly (P<0.05), but IL-10, IL-4, IL-5, and IL-1β increased significantly in the Rapa group (P<0.05). As for IL-10, IL-12p70, IL-2, IL-6, KC/GRO, and TNF-α, the therapy of Rapa combined with Elt showed a more significant effect than Rapa alone in AA mice. To some extent, this study had shown a relatively better synergistic effect in murine models of immune-mediated bone marrow failure after the combination therapy of Rapa and Elt, which was a promising clinical utility in SAA treatment.http://dx.doi.org/10.1155/2020/1798795
spellingShingle Shaoxue Ding
Xiaowei Liang
Tian Zhang
Rong Fu
The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure
Journal of Immunology Research
title The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure
title_full The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure
title_fullStr The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure
title_full_unstemmed The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure
title_short The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure
title_sort effectiveness of rapamycin combined with eltrombopag in murine models of immune mediated bone marrow failure
url http://dx.doi.org/10.1155/2020/1798795
work_keys_str_mv AT shaoxueding theeffectivenessofrapamycincombinedwitheltrombopaginmurinemodelsofimmunemediatedbonemarrowfailure
AT xiaoweiliang theeffectivenessofrapamycincombinedwitheltrombopaginmurinemodelsofimmunemediatedbonemarrowfailure
AT tianzhang theeffectivenessofrapamycincombinedwitheltrombopaginmurinemodelsofimmunemediatedbonemarrowfailure
AT rongfu theeffectivenessofrapamycincombinedwitheltrombopaginmurinemodelsofimmunemediatedbonemarrowfailure
AT shaoxueding effectivenessofrapamycincombinedwitheltrombopaginmurinemodelsofimmunemediatedbonemarrowfailure
AT xiaoweiliang effectivenessofrapamycincombinedwitheltrombopaginmurinemodelsofimmunemediatedbonemarrowfailure
AT tianzhang effectivenessofrapamycincombinedwitheltrombopaginmurinemodelsofimmunemediatedbonemarrowfailure
AT rongfu effectivenessofrapamycincombinedwitheltrombopaginmurinemodelsofimmunemediatedbonemarrowfailure